$BioVie Inc(BIVI)$ π ±ππ »π »π Έππ · π― $4.70
Heading to $4.70βοΈRide the π with me!
BIVI is jumping above VWAP & volume is picking up too π€
$4.70 π€« maybe too low ~ it is ready to reach at $5 very soon!!
@Tiger_comments @TigerPicks @TigerStars @TigerPM @Daily_Discussion @TigerObserver @TigerGPT
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Please analyze BioVie Inc (BIVI) as a professional financial analyst:
Business and Industry: BioVie Inc is a company in the biopharmaceutical industry. They focus on developing innovative therapies for patients with liver diseases and certain cancers. The biopharmaceutical industry is expected to experience growth in the future due to advancements in medical research and an increasing demand for new therapies.
Earnings and Earnings Forecast: Based on the latest earnings report, BioVie Inc reported an EPS of -2.20 for the second quarter of 2024. The company's financial performance indicates a negative profit margin and a negative return on investment. Looking at the earnings forecast, analysts expect the company to have a negative EPS of -4.41 for the fiscal year 2025 and -0.60 for the fiscal year 2026.
Recent Trends: The recent capital flow data shows fluctuations in the stock's trading volume. On November 8, there was a significant inflow of 240.59K units, followed by a smaller inflow on November 11. On November 12, there was a substantial inflow of 559.95K units, but on November 13, there was a minor inflow of 33.96K units. On November 14, there was a significant inflow of 520.99K units. The support price as of November 15 was $2.42, and the resistance price was $4.50.
Analyst Viewpoints: Currently, there is one analyst covering BioVie Inc, and their recommendation is to buy the stock. The analyst's target price is $5.00, suggesting potential upside.
Recent News: There is no specific news related to BioVie Inc within the given time frame.
Based on the analysis, it is essential to note that BioVie Inc's financial performance has been negative, with a negative EPS and profitability. The stock price is currently $3.19, which is below the average cost of $4.22. The analyst's target price is $5.00, indicating potential upside. However, this target price is based on one analyst's forecast and should be taken with caution.
Please consider that this analysis is for informational purposes only and should not be considered as investment advice. Investing in stocks carries inherent risks, and it is crucial to conduct further research and analysis before making any investment decisions.